CLCA2, a novel RUNX1 partner gene in a therapy-related leukemia with t(1;21)(p22;q22)

Cancer Genetics and Cytogenetics

Volumn 202, Issue 2, 2010, Pages 94-100

  Giguère, Amélie ^a,b   Hébert, Josée ^a,b  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CALCIUM ACTIVATED CHLORIDE CHANNEL; CHLORIDE CHANNEL; CYTARABINE; FLUDARABINE; IDARUBICIN; ISOPROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; CLCA2 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALTERNATIVE RNA SPLICING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CASE REPORT; CHROMOSOME 1P; CHROMOSOME 21Q; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 21; EXON; GENE FUSION; GENE MUTATION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; AMINO ACID SEQUENCE; CHROMOSOME 1; CHROMOSOME 21; FATALITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; KARYOTYPING; LEUKEMIA; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

AMINO ACID SEQUENCE; BASE SEQUENCE; CHLORIDE CHANNELS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 21; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA MUTATIONAL ANALYSIS; FATAL OUTCOME; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 77957049320     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.07.116     Document Type: Article

References (31)

1. Levanon D., Glusman G., Bangsow T., Ben-Asher E., Male D.A., Avidan N., et al. Architecture and anatomy of the genomic locus encoding the human leukemia-associated transcription factor RUNX1/AML1. Gene 2001, 262:23-33.
2. Mikhail F.M., Sinha K.K., Saunthararajah Y., Nucifora G. Normal and transforming functions of RUNX1: a perspective. J Cell Physiol 2006, 207:582-593.
3. Jeandidier E., Dastugue N., Mugneret F., Lafage-Pochitaloff M., Mozziconacci M.J., Herens C., et al. Abnormalities of the long arm of chromosome 21 in 107 patients with hematopoietic disorders: a collaborative retrospective study of the Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet 2006, 166:1-11.
4. Stevens-Kroef M.J., Schoenmakers E.F., van Kraaij M., Huys E., Vermeulen S., van der Reijden B., et al. Identification of truncated RUNX1 and RUNX1-PRDM16 fusion transcripts in a case of t(1;21)(p36;q22)-positive therapy-related AML. Leukemia 2006, 20:1187-1189.
5. Ramsey H., Zhang D.E., Richkind K., Burcoglu-O'Ral A., Hromas R. Fusion of AML1/Runx1 to copine VIII, a novel member of the copine family, in an aggressive acute myelogenous leukemia with t(12;21) translocation. Leukemia 2003, 17:1665-1666.
6. Mikhail F.M., Coignet L., Hatem N., Mourad Z.I., Farawela H.M., et al. A novel gene, FGA7, is fused to RUNX1/AML1 in a t(4;21)(q28;q22) in a patient with T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2004, 39:110-118.
7. Hromas R., Busse T., Carroll A., Mack D., Shopnick R., Zhang D.E., et al. Fusion AML1 transcript in a radiation-associated leukemia results in a truncated inhibitory AML1 protein. Blood 2001, 97:2168-2170.
8. LaFiura K.M., Edwards H., Taub J.W., Matherly L.H., Fontana J.A., Mohamed A.N., et al. Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group. Oncogene 2008, 27:4933-4942.
9. Zent C., Kim N., Hiebert S., Zhang D.E., Tenen D.G., Rowley J.D., et al. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties. Curr Top Microbiol Immunol 1996, 211:243-252.
10. Dai H.P., Xue Y.Q., Zhou J.W., Li A.P., Wu Y.F., Pan J.L., et al. LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation. Genes Chromosomes Cancer 2009, 48:1027-1036.
11. Nadal N., Stephan J.L., Cornillon J., Guyotat D., Flandrin P., Campos L. RUNX1 rearrangements in acute myeloblastic leukemia relapsing after hematopoietic stem cell transplantation. Cancer Genet Cytogenet 2008, 180:168-169.
12. ISCN 2009: an international system for human cytogenetic nomenclature 2009, S. Karger, Basel. L.G. Shaffer, M.L. Slovak, L.J. Campbell (Eds.).
13. Gruber A.D., Schreur K.D., Ji H.L., Fuller C.M., Pauli B.U. Molecular cloning and transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland. Am J Physiol 1999, 276:C1261-C1270.
14. 2+-activated chloride channel CLCA2. Cancer Res 1999, 59:5488-5491.
15. Stavropoulou C., Georgakakos V.N., Manola K.N., Pagoni M., Garofalaki M., Pantelias G.E., et al. 5′RARA submicroscopic deletion from new variant translocation involving chromosomes 15, 17, and 18, in a case of acute promyelocytic leukemia. Cancer Genet Cytogenet 2008, 182:50-55.
16. Kolomietz E., Al-Maghrabi J., Brennan S., Karaskova J., Minkin S., Lipton J., et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001, 97:3581-3588.
17. Zent C.S., Mathieu C., Claxton D.F., Zhang D.E., Tenen D.G., Rowley J.D., et al. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties. Proc Natl Acad Sci U S A 1996, 93:1044-1048.
18. Agerstam H., Lilljebjorn H., Lassen C., Swedin A., Richter J., Vandenberghe P., et al. Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 2007, 46:635-643.
19. Sakai I., Tamura T., Narumi H., Uchida N., Yakushijin Y., Hato T., et al. Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22). Genes Chromosomes Cancer 2005, 44:265-270.
20. Hazourli S., Chagnon P., Sauvageau M., Fetni R., Busque L., Hebert J. Overexpression of PRDM16 in the presence and absence of the RUNX1/PRDM16 fusion gene in myeloid leukemias. Genes Chromosomes Cancer 2006, 45:1072-1076.
21. Chinen Y., Taki T., Nishida K., Shimizu D., Okuda T., Yoshida N., et al. Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA. Oncogene 2008, 27:2249-2256.
22. Tanaka T., Tanaka K., Ogawa S., Kurokawa M., Mitani K., Nishida J., et al. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J 1995, 14:341-350.
23. Liu X., Zhang Q., Zhang D.E., Zhou C., Xing H., Tian Z., et al. Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis. Leukemia 2009, 23:739-745.
24. Yamashita N., Osato M., Huang L., Yanagida M., Kogan S.C., Iwasaki M., et al. Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. Br J Haematol 2005, 131:495-507.
25. Preudhomme C., Renneville A., Bourdon V., Philippe N., Roche-Lestienne C., Boissel N., et al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 2009, 113:5583-5587.
26. Elble R.C., Walia V., Cheng H.C., Connon C.J., Mundhenk L., Gruber A.D., et al. The putative chloride channel hCLCA2 has a single C-terminal transmembrane segment. J Biol Chem 2006, 281:29448-29454.
27. Abdel-Ghany M., Cheng H.C., Elble R.C., Pauli B.U. The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem 2001, 276:25438-25446.
28. Elble R.C., Pauli B.U. Tumor suppression by a proapoptotic calcium-activated chloride channel in mammary epithelium. J Biol Chem 2001, 276:40510-40517.
29. Walia V., Ding M., Kumar S., Nie D., Premkumar L.S., Elble R.C. hCLCA2 is a p53-inducible inhibitor of breast cancer cell proliferation. Cancer Res 2009, 69:6624-6632.
30. Li X., Cowell J.K., Sossey-Alaoui K. CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer. Oncogene 2004, 23:1474-1480.
31. Balakrishnan A., von Neuhoff N., Rudolph C., Kamphues K., Schraders M., Groenen P., et al. Quantitative microsatellite analysis to delineate the commonly deleted region 1p22.3 in mantle cell lymphomas. Genes Chromosomes Cancer 2006, 45:883-892.